Why Researchers Think This Matters Researchers believe these findings matter because semaglutide may influence brain pathways tied to reward, craving, mood, and stress response, not just appetite and metabolism
Research published in major obesity journals shows that patients on continuous GLP-1 therapy for 1224 months achieve weight losses of 1522% of body weight, compared to 23% in placebo groups
, ,
Lastly, weight gain is common with sulfonylurea and insulin therapy, whereas GLP-1 analogs induce weight loss and offset the weight gain associated with TZDs
Understanding how to naturally optimise your body's GLP-1 production through diet, lifestyle, and behavioural modifications offers an evidence-based approach to supporting metabolic health
However, always consult your healthcare professional about potential risks and benefits specific to your health condition